The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

Original citation: J Clin Invest. 2005;115(4):1068–1081. doi:10.1172/JCI22758.

Citation for this retraction: J Clin Invest. 2016;126(4):1603. doi:10.1172/JCI87345.

At the request of the corresponding author, the JCI is retracting this manuscript. The corresponding author recently notified the JCI that multiple microscopy images in Figure 2B were previously published and were used to represent different samples in another publication by the corresponding author’s group (1). The authors have stated that experimental data produced ad hoc are consistent with those in the original publication; however, the paper is being retracted due to data duplication and misrepresentation in the original publication.

Footnotes

See the related article beginning on page 1068.

References

1. Melillo RM, et al. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol. 2004;165(2):511–521.
   View this article via: PubMed CrossRef Google Scholar